Avances y Retos de la Nanobiotecnología Contra la Resistencia Antimicrobiana
DOI:
https://doi.org/10.29105/qh14.04-502Palabras clave:
Resistencia antimicrobiana (RAM), Nanobiotecnología, Nanomateriales, Mecanismos de resistencia bacterianos, Mecanismos de acción antimicrobianosResumen
La resistencia antimicrobiana (RAM) representa una amenaza global que compromete la eficacia terapéutica y la salud pública. Ante la disminución de nuevos antibióticos eficaces, la nanotecnología emerge como una alternativa prometedora para contrarrestar este fenómeno. El presente trabajo analiza los avances recientes en el uso de nanomateriales con propiedades antimicrobianas inherentes o como vehículos de liberación dirigida, destacando su capacidad para superar mecanismos de resistencia como bombas de eflujo, biopelículas y degradación enzimática. Asimismo, se abordan los principales retos asociados a su aplicación clínica, incluyendo la toxicidad, la producción a gran escala y las limitaciones regulatorias. Finalmente, se discuten las perspectivas futuras orientadas al diseño racional de nanomateriales más seguros y selectivos, así como su integración con terapias combinadas y herramientas de biología sintética. Estos enfoques multidisciplinarios podrían redefinir las estrategias terapéuticas frente a bacterias multirresistentes.
Descargas
Citas
- [1]. World Health Organization. (2023, noviembre 21). Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
- [2]. Dadgostar, P. (2019). Antimicrobial resistance: Implications and costs. Infection and Drug Resistance, 12, 3903–3910. https://doi.org/10.2147/IDR.S234610 DOI: https://doi.org/10.2147/IDR.S234610
- [3]. Karnwal, A., Jassim, A. Y., Mohammed, A. A., Al-Tawaha, A. R. M. S., Selvaraj, M., & Malik, T. (2025). Addressing the global challenge of bacterial drug resistance: Insights, strategies, and future directions. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1517772 DOI: https://doi.org/10.3389/fmicb.2025.1517772
- [4]. Desai, A., Ghosh, S., Sankaranarayanan, S., Bhatia, D. D., & Yadav, A. K. (2025). A One Health nanotechnologies approach to address antimicrobial resistance: State of the art and strategic outlook. Materials Advances. https://doi.org/10.1039/d5ma00487j DOI: https://doi.org/10.1039/D5MA00487J
- [5]. Khan, M., Wahab, S., Ali, H. M., Khan, S., Iqbal, R., & Khan, T. (2023). Biogenic nanomaterials: A way forward in preventing bacterial infections: Nanobiotechnology against resistant pathogens. Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences, 60(S), 3–23. https://doi.org/10.53560/PPASB(60-sp1)814 DOI: https://doi.org/10.53560/PPASB(60-sp1)814
- [6]. Fagbemi, N. O. A., Essuah, N. M., Ugwu, N. D. C., Ajibola, N. A. B., Onyeyili, N. I. N., & Ojo-Omoniyi, N. D. S. (2025). Nanobiotechnology-driven innovations for tackling antimicrobial resistance. World Journal of Biology Pharmacy and Health Sciences, 21(2), 300–328. https://doi.org/10.30574/wjbphs.2025.21.2.0093 DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0093
- [7]. El-Habib, I., Dine, S., Lemarchand, A., Mielcarek, C., Traore, M., & Azouani, R. (2024, junio 28). Increased antimicrobial activity of ZnO nanoparticle thin films: Effect of surface structuration. arXiv. https://arxiv.org/abs/2407.02525
- [8]. Tariq, S., Iqbal, T., Khokhar, A. M., Azmat, U., Narejo, G. F., & Aslam, M. (2024). Developing and characterization of silver nanoparticles with enhanced antimicrobial activity to combat multidrug-resistant bacteria. Azerbaijan Pharmaceutical and Pharmacotherapy Journal, 23(3), 1–12.
- [9]. Ahmad, N., Bukhari, S. N. A., Hussain, M. A., Ejaz, H., Munir, M. U., & Amjad, M. W. (2024). Nanoparticles incorporated hydrogels for delivery of antimicrobial agents: Developments and trends. RSC Advances, 14(19), 13535–13564. https://doi.org/10.1039/d4ra00631c DOI: https://doi.org/10.1039/D4RA00631C
- [10]. Marchetti, M. L., Errecalde, J. O., & Mestorino, O. N. (2011). Resistencia bacteriana a los antimicrobianos ocasionada por bombas de eflujo. Analecta Veterinaria, 31.
- [11]. Gaurav, A., Bakht, P., Saini, M., Pandey, S., & Pathania, R. (2023). Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology, 169(5), 001333. https://doi.org/10.1099/mic.0.001333 DOI: https://doi.org/10.1099/mic.0.001333
- [12]. Dulanto Chiang, A., & Dekker, J. P. (2024). Efflux pump-mediated resistance to new beta-lactam antibiotics in multidrug-resistant gram-negative bacteria. Communications Medicine, 4(1), 170. https://doi.org/10.1038/s43856-024-00591-y DOI: https://doi.org/10.1038/s43856-024-00591-y
- [13]. Schaenzer, A. J., & Wright, G. D. (2020). Antibiotic resistance by enzymatic modification of antibiotic targets. Trends in Molecular Medicine, 26(8), 768–782. https://doi.org/10.1016/j.molmed.2020.05.001 DOI: https://doi.org/10.1016/j.molmed.2020.05.001
- [14]. Halawa, E. M., Fadel, M., Al-Rabia, M. W., Behairy, A., Nouh, N. A., Abdo, M., Olga, R., Fericean, L., Atwa, A. M., & Abdeen, A. (2024). Antibiotic action and resistance: Updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Frontiers in Pharmacology, 14, 1305294. https://doi.org/10.3389/fphar.2023.1305294 DOI: https://doi.org/10.3389/fphar.2023.1305294
- [15]. Agarwal, V., Tiwari, A., & Varadwaj, P. (2023). An extensive review on β-lactamase enzymes and their inhibitors. Current Medicinal Chemistry, 30(7), 783–808. https://doi.org/10.2174/0929867329666220620165429 DOI: https://doi.org/10.2174/0929867329666220620165429
- [16]. Nahar, L., Hagiya, H., Gotoh, K., Asaduzzaman, M., & Otsuka, F. (2024). New Delhi metallo-beta-lactamase inhibitors: A systematic scoping review. Journal of Clinical Medicine, 13(14), 4199. https://doi.org/10.3390/jcm13144199 DOI: https://doi.org/10.3390/jcm13144199
- [17]. Alarcia-Lacalle, A., Canut-Blasco, A., Solinís, M. Á., Isla, A., & Rodríguez-Gascón, A. (2025). Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: A systematic review. JAC-Antimicrobial Resistance, 7(3), dlaf096. https://doi.org/10.1093/jacamr/dlaf096 DOI: https://doi.org/10.1093/jacamr/dlaf096
- [18]. Uruén, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R. C., & Arenas, J. (2021). Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics, 10(1), 3. https://doi.org/10.3390/antibiotics10010003 DOI: https://doi.org/10.3390/antibiotics10010003
- [19]. Liu, H. Y., Prentice, E. L., & Webber, M. A. (2024). Mechanisms of antimicrobial resistance in biofilms. npj Antimicrobial Resistance, 2, 27. https://doi.org/10.1038/s44259-024-00046-3 DOI: https://doi.org/10.1038/s44259-024-00046-3
- [20]. Bangar, S. P., Whiteside, W. S., Kajla, P., & Tavassoli, M. (2025). A review of advancements, properties, and challenges of carbon nanotubes in food packaging. Journal of Food Measurement and Characterization, 1–23. DOI: https://doi.org/10.1007/s11694-025-03127-7
- [21]. Kang, S., Pinault, M., Pfefferle, L. D., & Elimelech, M. (2007). Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langmuir, 23(17), 8670–8673. DOI: https://doi.org/10.1021/la701067r
- [22]. Saleemi, M. A., Kong, Y. L., Yong, P. V. C., & Wong, E. H. (2021). An overview of antimicrobial properties of carbon nanotubes-based nanocomposites. Advanced Pharmaceutical Bulletin, 12(3), 449. DOI: https://doi.org/10.34172/apb.2022.049
- [23]. Moskvitina, E., Kuznetsov, V., Moseenkov, S., Serkova, A., & Zavorin, A. (2023). Antibacterial effect of carbon nanomaterials: Nanotubes, carbon nanofibers, nanodiamonds, and onion-like carbon. Materials, 16(3), 957. DOI: https://doi.org/10.3390/ma16030957
- [24]. Azizi-Lalabadi, M., Hashemi, H., Feng, J., & Jafari, S. M. (2020). Carbon nanomaterials against pathogens: The antimicrobial activity of carbon nanotubes, graphene/graphene oxide, fullerenes, and their nanocomposites. Advances in Colloid and Interface Science, 284, 102250. DOI: https://doi.org/10.1016/j.cis.2020.102250
- [25]. Bolshakova, O., Lebedev, V., Mikhailova, E., Zherebyateva, O., Aznabaeva, L., Burdakov, V., ... & Sarantseva, S. (2023). Fullerenes on a nanodiamond platform demonstrate antibacterial activity with low cytotoxicity. Pharmaceutics, 15(7), 1984. DOI: https://doi.org/10.3390/pharmaceutics15071984
- [26]. Aoshima, H., Kokubo, K., Shirakawa, S., Ito, M., Yamana, S., & Oshima, T. (2009). Antimicrobial activity of fullerenes and their hydroxylated derivatives. Biocontrol Science, 14(2), 69–72. DOI: https://doi.org/10.4265/bio.14.69
- [27]. Slavin, Y. N., Asnis, J., Häfeli, U. O., & Bach, H. (2017). Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. Journal of Nanobiotechnology, 15(1), 65. DOI: https://doi.org/10.1186/s12951-017-0308-z
- [28]. Tang, S., & Zheng, J. (2018). Antibacterial activity of silver nanoparticles: Structural effects. Advanced Healthcare Materials, 7(13), 1701503. DOI: https://doi.org/10.1002/adhm.201701503
- [29]. Martínez-Castañón, G. A., Niño-Martínez, N., Martínez-Gutiérrez, F., Martínez-Mendoza, J. R., & Ruiz, F. (2008). Synthesis and antibacterial activity of silver nanoparticles with different sizes. Journal of Nanoparticle Research, 10(8), 1343–1348. DOI: https://doi.org/10.1007/s11051-008-9428-6
- [30]. Sathiyaraj, S., Suriyakala, G., Gandhi, A. D., Babujanarthanam, R., Almaary, K. S., Chen, T. W., & Kaviyarasu, K. (2021). Biosynthesis, characterization, and antibacterial activity of gold nanoparticles. Journal of Infection and Public Health, 14(12), 1842–1847. DOI: https://doi.org/10.1016/j.jiph.2021.10.007
- [31]. Chatterjee, A. K., Chakraborty, R., & Basu, T. (2014). Mechanism of antibacterial activity of copper nanoparticles. Nanotechnology, 25(13), 135101. DOI: https://doi.org/10.1088/0957-4484/25/13/135101
- [32]. Cao, Y., Gong, Y., Liu, L. L., Zhou, Y. W., Fang, X., Zhang, C., Li, Y. N., & Li, J. (2017). The use of human umbilical vein endothelial cells (HUVECs) as an in vitro model to assess the toxicity of nanoparticles to endothelium: A review. Journal of Applied Toxicology, 37, 1359–1369. DOI: https://doi.org/10.1002/jat.3470
- [33]. Bello, D., & Warheit, D. B. (2017). Biokinetics of engineered nano-TiO₂ in rats administered by different exposure routes: Implications for human health. Nanotoxicology, 11, 431–433. DOI: https://doi.org/10.1080/17435390.2017.1330436
- [34]. Simonin, M., Martins, J. M. F., Uzu, G., Vince, E., & Richaume, A. (2016). Combined study of titanium dioxide nanoparticle transport and toxicity on microbial nitrifying communities under single and repeated exposures in soil columns. Environmental Science & Technology, 50, 10693–10699. DOI: https://doi.org/10.1021/acs.est.6b02415
- [35]. Cvjetko, P., Milosic, A., Domijan, A. M., Vrcek, I. V., Tolic, S., Stefanic, P. P., Letofsky Papst, I., Tkalec, M., & Balen, B. (2017). Toxicity of silver ions and differently coated silver nanoparticles in Allium cepa roots. Ecotoxicology and Environmental Safety, 137, 18–28. DOI: https://doi.org/10.1016/j.ecoenv.2016.11.009
- [36]. Rizwan, M., Ali, S., Qayyum, M. F., Ok, Y. S., Adrees, M., Ibrahim, M., Zia-ur-Rehman, M., Farid, M., & Abbas, F. (2017). Effect of metal and metal oxide nanoparticles on growth and physiology of globally important food crops: A critical review. Journal of Hazardous Materials, 322, 2–16. DOI: https://doi.org/10.1016/j.jhazmat.2016.05.061
- [37]. Medina-Pérez, G., & Fernández-Luqueño, F. (2018). Nanotoxicidad: Retos y oportunidades. Mundo Nano, 11(20), 7–16. DOI: https://doi.org/10.22201/ceiich.24485691e.2018.20.64105
- [38]. Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022). Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano, 7, 100048. https://doi.org/10.1016/j.onano.2022.100048 DOI: https://doi.org/10.1016/j.onano.2022.100048
- [39]. U.S. Food and Drug Administration. (2024, mayo 15). Considerations for drug products that contain nanomaterials. https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/considerations-drug-products-contain-nanomaterials
- [40]. Oualikene-Gonin, W., Sautou, V., Ezan, E., Bastos, H., Bellissant, E., Belgodère, L., Maison, P., & Ankri, J. (2023). Regulatory assessment of nano-enabled health products in public health interest: Position of the Scientific Advisory Board of the ANSM. Frontiers in Public Health, 11, 1125577. https://doi.org/10.3389/fpubh.2023.1125577 DOI: https://doi.org/10.3389/fpubh.2023.1125577
- [41]. Shan, X., Cai, Y., Zhu, B., Zhou, L., Sun, X., Xu, X., Yin, Q., Wang, D., & Li, Y. (2024). Rational strategies for improving the efficiency of design and discovery of nanomedicines. Nature Communications, 15(1), 9990. https://doi.org/10.1038/s41467-024-54265-3 DOI: https://doi.org/10.1038/s41467-024-54265-3
- [42]. Saffari Natanzi, A., Poudineh, M., Karimi, E., et al. (2025). Innovative approaches to combat antibiotic resistance: Integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections. BMC Medicine, 23, 486. https://doi.org/10.1186/s12916-025-04323-4 DOI: https://doi.org/10.1186/s12916-025-04323-4
- [43]. de la Fuente Tagarro, C., Martín-González, D., De Lucas, A., Bordel, S., & Santos-Beneit, F. (2024). Current knowledge on CRISPR strategies against antimicrobial-resistant bacteria. Antibiotics, 13(12), 1141. https://doi.org/10.3390/antibiotics13121141 DOI: https://doi.org/10.3390/antibiotics13121141
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Itzel Atziri Díaz Rodrígueza, Jonathan Martínez Alvizo, Xristo Zárate Kalfópulos, José Rubén Morones Ramírez
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
